www.medical-devices.tech
23
'25
Written on Modified on
3D Bioprinting Offers Path to Safer Surgeries and Fewer Infections
Bioprinted tissues accelerate healing through natural integration, reducing infection, scarring, and recovery times compared to traditional implants or synthetic substitutes.
vital3d.eu
Hospital-acquired infections and transplant complications remain persistent risks in healthcare, but 3D bioprinting offers a promising approach by creating sterile, patient-specific tissues that reduce contamination and immune rejection. This technology may lower infection rates, decrease reliance on antibiotics, and improve healing times by enabling better bodily integration.
Healthcare-associated infections (HAIs) remain a significant concern in modern medicine, with approximately 1 in 31 hospital patients in the US experiencing at least one infection on any given day. These infections, along with surgical complications and immune rejection of transplants, contribute to extended recovery times, increased healthcare costs, and higher mortality rates. In the EU alone, more than 3.5 million cases of HAI are reported each year, leading to more than 90 thousand deaths annually.
3D bioprinting technology offers a promising solution to these challenges. By creating patient-specific, biocompatible tissues and structures using a patient's own cells, this technology has the potential to significantly reduce infection risks, minimize immune rejection, and improve surgical outcomes across various medical fields.
How bioprinting could reduce infection and improve safety
Bioprinting takes place in controlled laboratory environments that maintain strict sterility standards, reducing contamination risks compared to traditional donor tissues or synthetic implants.
"Bioprinting is typically done in cleanroom environments or biosafety cabinets that are HEPA-filtered to remove particulates, microbes, and spores,” says Vidmantas Šakalys, CEO of Vital3D Technologies, a biotech company that specializes in 3D bioprinting solutions. “Traditional donor tissue, by contrast, is often harvested in hospitals or operating rooms, where sterility is harder to maintain over long distances and times."
The technology also reduces contamination risk through decreased handling time. “Bioprinted tissues can be created shortly before use, minimizing storage time and exposure,” explains Šakalys. “They're tailored to specific patient needs, reducing the need for post-processing or modification that introduces contamination opportunities. Traditional implants often sit in storage or are mass-produced, increasing the need for repeated sterilization cycles and risk of contamination during transport.”
Reducing antibiotic usage through personalized implants
The overuse of antibiotics to treat infections is a leading contributor to developing drug-resistant pathogens, according to the WHO, which estimates that antimicrobial resistance (AMR) could result in $1 trillion in additional healthcare costs by 2050. Bioprinted tissues and implants aim to address the issue early by reducing infection instances, therefore decreasing the need for antibiotic medications during and after surgical procedures.
“Bioprinted implants, especially when made from the patient’s own cells, are more biocompatible, leading to less inflammation, lower risk of infection, and reduced need for prophylactic antibiotics during and after surgery,” says Šakalys. “Donor tissues can carry latent infections or contamination risks despite sterilization, while bioprinted tissues are made in sterile, controlled environments, minimizing contamination and avoiding post-op antibiotic treatments.”
Post-op antibiotics are often required when surgical revisions are needed, due to infection or poor implant fit. Bioprinted implants tend to reduce such complications, resulting in fewer repeat surgeries and less antibiotic use over time.
Bioprinting technology also allows for more targeted infection prevention. According to Šakalys, “Bioprinted tissues can be engineered to release localized antimicrobial agents, like silver nanoparticles, antimicrobial peptides, and localized antibiotics. This allows targeted infection prevention without systemic antibiotic use.”
Accelerating healing and recovery times
Beyond infection prevention, bioprinted tissues show potential to speed healing times through more natural integration with the body's systems.
“Bioprinting can reduce healing time—and in some cases, dramatically—by enabling more natural, personalized, and biologically active tissue integration compared to traditional implants or grafts,” says Šakalys. “Bioprinted bone scaffolds seeded with osteoblasts or stem cells have shown faster bone regeneration than traditional grafts in preclinical trials.”
This technology is already showing promise in commercial applications. L’Oréal, in collaboration with research institutions, has developed bioprinted skin that can replicate various skin conditions, with potential applications for treating burn patients more effectively than traditional skin grafts.
According to Šakalys, other applications are equally promising: “Bioprinted skin grafts using keratinocytes and fibroblasts have demonstrated faster wound closure, better re-epithelialization, and reduced scar formation compared to synthetic skin substitutes. Bioprinted cardiac patches using patient-specific heart cells help the heart remodel more quickly after injury by promoting synchronized contraction and healing.”
www.vital3d.com
Healthcare-associated infections (HAIs) remain a significant concern in modern medicine, with approximately 1 in 31 hospital patients in the US experiencing at least one infection on any given day. These infections, along with surgical complications and immune rejection of transplants, contribute to extended recovery times, increased healthcare costs, and higher mortality rates. In the EU alone, more than 3.5 million cases of HAI are reported each year, leading to more than 90 thousand deaths annually.
3D bioprinting technology offers a promising solution to these challenges. By creating patient-specific, biocompatible tissues and structures using a patient's own cells, this technology has the potential to significantly reduce infection risks, minimize immune rejection, and improve surgical outcomes across various medical fields.
How bioprinting could reduce infection and improve safety
Bioprinting takes place in controlled laboratory environments that maintain strict sterility standards, reducing contamination risks compared to traditional donor tissues or synthetic implants.
"Bioprinting is typically done in cleanroom environments or biosafety cabinets that are HEPA-filtered to remove particulates, microbes, and spores,” says Vidmantas Šakalys, CEO of Vital3D Technologies, a biotech company that specializes in 3D bioprinting solutions. “Traditional donor tissue, by contrast, is often harvested in hospitals or operating rooms, where sterility is harder to maintain over long distances and times."
The technology also reduces contamination risk through decreased handling time. “Bioprinted tissues can be created shortly before use, minimizing storage time and exposure,” explains Šakalys. “They're tailored to specific patient needs, reducing the need for post-processing or modification that introduces contamination opportunities. Traditional implants often sit in storage or are mass-produced, increasing the need for repeated sterilization cycles and risk of contamination during transport.”
Reducing antibiotic usage through personalized implants
The overuse of antibiotics to treat infections is a leading contributor to developing drug-resistant pathogens, according to the WHO, which estimates that antimicrobial resistance (AMR) could result in $1 trillion in additional healthcare costs by 2050. Bioprinted tissues and implants aim to address the issue early by reducing infection instances, therefore decreasing the need for antibiotic medications during and after surgical procedures.
“Bioprinted implants, especially when made from the patient’s own cells, are more biocompatible, leading to less inflammation, lower risk of infection, and reduced need for prophylactic antibiotics during and after surgery,” says Šakalys. “Donor tissues can carry latent infections or contamination risks despite sterilization, while bioprinted tissues are made in sterile, controlled environments, minimizing contamination and avoiding post-op antibiotic treatments.”
Post-op antibiotics are often required when surgical revisions are needed, due to infection or poor implant fit. Bioprinted implants tend to reduce such complications, resulting in fewer repeat surgeries and less antibiotic use over time.
Bioprinting technology also allows for more targeted infection prevention. According to Šakalys, “Bioprinted tissues can be engineered to release localized antimicrobial agents, like silver nanoparticles, antimicrobial peptides, and localized antibiotics. This allows targeted infection prevention without systemic antibiotic use.”
Accelerating healing and recovery times
Beyond infection prevention, bioprinted tissues show potential to speed healing times through more natural integration with the body's systems.
“Bioprinting can reduce healing time—and in some cases, dramatically—by enabling more natural, personalized, and biologically active tissue integration compared to traditional implants or grafts,” says Šakalys. “Bioprinted bone scaffolds seeded with osteoblasts or stem cells have shown faster bone regeneration than traditional grafts in preclinical trials.”
This technology is already showing promise in commercial applications. L’Oréal, in collaboration with research institutions, has developed bioprinted skin that can replicate various skin conditions, with potential applications for treating burn patients more effectively than traditional skin grafts.
According to Šakalys, other applications are equally promising: “Bioprinted skin grafts using keratinocytes and fibroblasts have demonstrated faster wound closure, better re-epithelialization, and reduced scar formation compared to synthetic skin substitutes. Bioprinted cardiac patches using patient-specific heart cells help the heart remodel more quickly after injury by promoting synchronized contraction and healing.”
www.vital3d.com
